Hilliard Lyons Downgrades Abbott Labs (ABT) to Long-Term Buy
More News related to ABT
- Abbott (ABT) Seeks for ARCHITECT HE4 to be First Automated HE4 Test Available in the U.S.
- Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
- Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
- First Global Upgrades Abbot Labs (ABT) to Long Term Outperform
- Absolute Software's Computer Lifecycle Management Solution Selected by University of Texas
More News related to Downgrades
- Wells Fargo Downgrades Parkway Properties (PKY) to Underperform
- Piper Jaffray Downgrades Telvent Git S.A. (TLVT) to Neutral; Recommend Sidelines on Potentially Weaker Spain Business
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
Hilliard Lyons downgrades Abbott Labs (NYSE: ABT) from Buy to Long-Term Buy. Price target raised from $55 to $80.
To see all the upgrades/downgrades on shares of ABT, visit our Analyst Ratings page.
Abbott Laboratories manufactures and sells health care products worldwide.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
